Previous 10 | Next 10 |
2024-02-23 06:03:58 ET Summary Rhythm Pharmaceuticals focuses on treating obesity caused by genetic mutations, but the market size for these mutations is too small to justify the company's valuation. Novo Nordisk's Ozempic also targets the same patient groups, making Rhythm's prod...
2024-02-22 23:33:09 ET Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2023 Earnings Conference Call February 22, 2024 08:00 AM ET Company Participants David Connolly - Executive Director, IR and Corporate Communications David Meeker - Chairman, President, and CEO Jennife...
2024-02-21 11:01:15 ET More on Rhythm Pharmaceuticals Rhythm completes screening for Phase 3 anti-obesity study Rhythm to acquire rights to Phase 2 anti-obesity drug from LG Chem Seeking Alpha’s Quant Rating on Rhythm Pharmaceuticals Historical earning...
2024-02-21 09:42:51 ET Major earnings expected before the bell on Thursday include: Dominion Energy ( D ) Iron Mountain ( IRM ) Moderna ( MRNA ) Newmont ( NEM ) Nikola ( NKLA ) Read the full article on Seeking Alpha For further details...
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Italian Medicine Agency (A...
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference...
2024-01-21 22:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...
2024-01-04 10:48:31 ET More on Rhythm Pharmaceuticals Rhythm Pharmaceuticals: Major Catalysts Due For Weight Loss Specialist Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2023 Earnings Call Transcript Rhythm Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentati...
2024-01-04 09:51:10 ET More on Rhythm Pharmaceuticals Rhythm Pharmaceuticals: Major Catalysts Due For Weight Loss Specialist Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2023 Earnings Call Transcript Rhythm Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentati...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
-- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
-- First quarter 2024 net revenue from global sales of IMCIVREE ® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 years old in approved indications in second quarter of 2024 -- --...